RE:RE:RE:Cash burn at AEZSPediatric enrollment for AEZS's diagnostic test clinical trial is expected by the end of the year according to a filing last month. The end of the year is basically here. The results from a diagnostic test may not take that long to compile. That could be the basis for signing a new North American licensing deal for the test. Gilles should have a very good idea how negotiations with potential partners are going. Could we get pediatric trial results for the test and a North American licensing deal before shareholders vote on the deal? That could help with support. It seems like a much needed test and a one and only... Clinical results in children and a North American licensing deal could help drive the stock towards HC Wainwright's target price. I'm intrigued by what Novo Nordisk invested...
...US$145 million plus tiered royalties and an equity investment worth more than US$36 million... That's close to C$250 million in cash and equity plus tiered royalties. lscfa wrote: Maybe closer to $24M/yr revenue. Novo originally agreed to a 15% royalty but is was reduced to 7.5% when they accelerated an upfront payment. Also, the European license is for royalties in the 10% to 20% range.